DEVINTEC Sagl

DEVINTEC Sagl, which operates under the brand name Devintec Pharma, is a privately owned pharmaceutical company based in Lugano, Switzerland. The company positions itself as a pioneer in researching and developing innovative substance-based medical devices — therapeutic products whose mode of action is physical or physicochemical rather than purely pharmacological, and which are regulated as medical devices rather than as drugs. Its stated mission is to develop innovative etiological treatments that restore natural epithelial permeability, addressing the underlying causes of conditions linked to compromised epithelial barriers. Devintec Pharma was created to drive Novintethical Global Market Access. Novintethical Pharma SA, the related entity referenced in the company's own materials, was founded in 2009. Devintec applies clinical and regulatory standards that have brought to life more than 20 projects of innovative evidence-based medical devices, with seven projects in clinical development. In 2019 the company reported investing 30% of its turnover in research and development, underscoring a research-intensive positioning unusual for a small privately held firm. The company's know-how spans the full development chain: market development (defining patient-relevant added value and outcomes and matching unmet needs with research), research (discovery and pre-clinical raw material testing), development (technical formulation, pre-clinical safety, mode-of-action and efficacy testing, industrial batch and stability work, and final specification), regulatory approval, clinical validation, and post-market surveillance and vigilance. Its team is organized around business development and licensing, partners and operations management, scientific and medical marketing, scientific and medical affairs, and quality assurance and regulatory affairs. Because Devintec is privately owned and does not disclose detailed financials publicly, its scale is modest relative to large pharmaceutical groups; its visibility rests instead on its pipeline of substance-based medical device projects and its regulatory and clinical capabilities. The company remains active, headquartered in Lugano, and continues to describe itself as a pioneer in the substance-based medical device field.

DEVINTEC Sagl is a Swiss company based in Lugano that operates under the brand name Devintec Pharma. According to the company's own materials, Devintec Pharma was created to drive Novintethical Global Market Access, and Novintethical Pharma SA — the related entity — was founded in 2009. This places the origins of the Devintec/Novintethical effort in the late 2000s, when the founders set out to build a business around a then-emerging category: substance-based medical devices. Substance-based medical devices are therapeutic products whose action is based on physical or physicochemical mechanisms — for example forming a protective film or restoring a barrier — rather than on pharmacological activity. Because they are regulated as medical devices rather than as medicinal products, they require a distinct clinical and regulatory pathway. Devintec built its identity around mastering that pathway. The company states that it applies clinical and regulatory standards that have brought to life more than 20 projects of innovative evidence-based medical devices, with seven projects in clinical development. In 2019 it reported investing 30% of its turnover in research and development, a figure that signals a research-intensive, pipeline-driven business model. Over time the company has articulated a full development methodology spanning market development, research, development, regulatory approval, clinical validation, and post-market surveillance and vigilance. Its market-development work focuses on defining patient-relevant added value and outcomes and matching unmet needs with research; its research work covers discovery and pre-clinical raw-material testing; its development work covers technical formulation, pre-clinical safety, mode-of-action and efficacy testing, industrial batch and stability studies, and final specification. This end-to-end approach is presented as the company's core know-how. The company is privately owned and headquartered in Lugano, Switzerland, and it describes itself as a privately owned pharmaceutical company. It does not appear to be listed on a public exchange, and no parent company is disclosed in the available evidence. Its team is organized around business development and licensing, partners and operations management, scientific and medical marketing, scientific and medical affairs, and quality assurance and regulatory affairs — functions consistent with a firm whose value lies in clinical evidence and regulatory approvals rather than in manufacturing scale. As of the available evidence, Devintec remains active, continues to position itself as a pioneer in substance-based medical devices, and maintains its mission of developing innovative etiological treatments to restore natural epithelial permeability.

• 2019

  Devintec reported investing 30% of its turnover in research and development.

• 2009

  Novintethical Pharma SA, the related entity referenced by Devintec Pharma, was founded.

Pioneer in researching and developing innovative substance-based medical devices, with a mission to develop etiological treatments restoring natural epithelial permeability.

• Substance-based medical devices (R&D portfolio)

  More than 20 projects of innovative evidence-based medical devices, with 7 projects in clinical development.

1. 1Devintec - Advanced R&D in substance-based medical devices - Devintec Pharmadevintecpharma.com
2. 2Who We Are - Devintec Pharmadevintecpharma.com
3. 3DEVINTEC Sagl (Switzerland) - Wikidatawikidata.org